HEARTCARE-B：ANNOUNCEMENTOFANNUALRESULTSFORTHEYEARENDEDDECEMBER312025.pdf

1、 1 Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in rel

2、iance upon the whole or any part of the contents of this announcement.Shanghai HeartCare Medical TechnologyCorporation Limited上海心瑋醫療科技股份有限公司(A joint stock company incorporated in the Peoples Republic of China with limited liability)(Stock Code:6609)ANNOUNCEMENT OF ANNUAL RESULTSFOR THE YEAR ENDED DE

3、CEMBER 31,2025FINANCIAL HIGHLIGHTSYear endedDecember 31,2025Year endedDecember 31,2024Period-to-period changeRMB000RMB000Revenue408,286277,89946.9%Gross profit289,521181,71659.3%Gross profit margin70.9%65.4%5.5 percentage pointsSelling&distribution and administrative expenses187,119137,80535.8%Resea

4、rch and development costs40,76158,94030.8%Profit/(Loss)before tax86,408(11,992)820.5%Profit/(Loss)and total comprehensive profit/(loss)for the year83,335(13,622)711.8%2 BUSINESS HIGHLIGHTIn the fiscal year 2025,the Company recorded revenue of RMB408.3 million,representing a year-on-year increase of

5、46.9%.The Group recorded a net profit attributable to the Shareholders of RMB83.3 million,a significant turnaround from the net loss attributable to the Shareholders of approximately RMB13.6 million in the prior year.This transformation is primarily attributable to the rapid revenue growth in the Co

6、mpanys ischemic stroke,hemorrhagic stroke and interventional access businesses,coupled with the further improvement in the Companys operational efficiency.In 2025,the revenue from the ischemic stroke business increased by 31.8%year-on-year,primarily due to(1)the Companys Aspiration Catheter with dif